Obliterated by Alzheimer's failure, Neurotrope relinquishes its Nasdaq spot in reverse merger

Obliterated by Alzheimer's failure, Neurotrope relinquishes its Nasdaq spot in reverse merger

Source: 
Endpoints
snippet: 

Battered after a spectacular failure with its Alzheimer’s drug candidate, Neurotrope Biosciences is being absorbed by a privately-held company that makes an erectile dysfunction (ED) treatment.